{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:03:34Z","timestamp":1790643814967,"version":"4.1.0"},"reference-count":94,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"vor","delay-in-days":366,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.bbadis.2014.06.013","type":"journal-article","created":{"date-parts":[[2014,6,17]],"date-time":"2014-06-17T06:05:17Z","timestamp":1402985117000},"page":"658-666","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":105,"title":["Pathogenesis of immune-mediated neuropathies"],"prefix":"10.1016","volume":"1852","author":[{"given":"Marinos C.","family":"Dalakas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbadis.2014.06.013_bb0005","series-title":"Clinical Immunology: Principles and Practice","first-page":"977","article-title":"Autoimmune peripheral neuropathies","author":"Dalakas","year":"2011"},{"key":"10.1016\/j.bbadis.2014.06.013_bb0010","series-title":"Pathophysiology of Autoimmune Polyneuropathies Presse Medicale","author":"Dalakas","year":"2013"},{"key":"10.1016\/j.bbadis.2014.06.013_bb0015","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1056\/NEJMra1114525","article-title":"Guillain\u2013Barr\u00e9 syndrome","volume":"366","author":"Yuki","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0020","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S0140-6736(05)67665-9","article-title":"Guillain\u2013Barr\u00e9 syndrome","volume":"366","author":"Hughes","year":"2005","journal-title":"Lancet"},{"issue":"1\u20132","key":"10.1016\/j.bbadis.2014.06.013_bb0025","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jneuroim.2010.09.017","article-title":"Guillain\u2013Barr\u00e9 syndrome: clinical variants and their pathogenesis","volume":"231","author":"Winer","year":"2011","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0030","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0022-510X(93)90324-R","article-title":"Severe axonal degeneration in acute Guillain\u2013Barr\u00e9 syndrome: evidence of two different mechanisms?","volume":"116","author":"Feasby","year":"1993","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0035","doi-asserted-by":"crossref","first-page":"11404","DOI":"10.1073\/pnas.0402391101","article-title":"Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain\u2013Barr\u00e9 syndrome","volume":"101","author":"Yuki","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0040","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1093\/brain\/awf272","article-title":"Peripheral neuropathies and anti-glycolipid antibodies","volume":"125","author":"Willison","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.bbadis.2014.06.013_bb0045","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/j.1471-4159.2010.07029.x","article-title":"Antibodies against ganglioside complexes in Guillain\u2013Barr\u00e9 syndrome and related disorders","volume":"116","author":"Kusunoki","year":"2011","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0050","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrneurol.2011.121","article-title":"Advances in the diagnosis, pathogenesis and treatment of CIDP","volume":"7","author":"Dalakas","year":"2011","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0055","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1136\/jnnp.66.5.677","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England","volume":"66","author":"Lunn","year":"1999","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.bbadis.2014.06.013_bb0060","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1085-9489.2006.00061.x","article-title":"Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy","volume":"11","author":"Hughes","year":"2006","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0065","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(10)70041-7","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition","volume":"9","author":"Vallat","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0070","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1212\/01.wnl.0000188879.19900.b7","article-title":"Macrophage clustering as a diagnostic marker in sural nerve biopsies of patients with CIDP","volume":"65","author":"Sommer","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.bbadis.2014.06.013_bb0075","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/019131200750060023","article-title":"Chronic inflammatory demyelinating polyneuropathy: immunopathological and ultrastructural study of peripheral nerve biopsy in 42 cases","volume":"24","author":"Vital","year":"2000","journal-title":"Ultrastruct. Pathol."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0080","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMra041347","article-title":"Chronic inflammatory demyelinating polyneuropathy","volume":"352","author":"Koller","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0085","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1474-4422(05)70074-0","article-title":"Multifocal motor neuropathy","volume":"4","author":"Van Asseldonk","year":"2005","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.bbadis.2014.06.013_bb0090","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1136\/jnnp.2010.205856","article-title":"IVIG blocks complement deposition mediated by anti-GM1 antibodies in multifocal motor neuropathy","volume":"82","author":"Yuki","year":"2011","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.bbadis.2014.06.013_bb0095","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/ana.410390402","article-title":"Autoimmune ataxic neuropathies (sensory ganglionopathies): are glycolipids the responsible autoantigens?","volume":"39","author":"Dalakas","year":"1996","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0100","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/ana.410380214","article-title":"Acute axonal Guillain\u2013Barr\u00e9 syndrome with IgG antibodies against motor axons following parenteral gangliosides","volume":"38","author":"Illa","year":"1995","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0105","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.it.2003.12.004","article-title":"The Guillain\u2013Barr\u00e9 syndrome: a true case of molecular mimicry","volume":"25","author":"Ang","year":"2004","journal-title":"Trends Immunol."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0110","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0022-510X(76)90213-6","article-title":"Chronic relapsing polyneuritis","volume":"27","author":"Prineas","year":"1976","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0115","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/00019052-199908000-00006","article-title":"Advances in chronic inflammatory demyelinating polyneuropathy: disease variants and inflammatory response mediators and modifiers","volume":"12","author":"Dalakas","year":"1999","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0120","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1093\/brain\/123.8.1660","article-title":"Expression of the co-stimulatory molecule BB-1, the ligands CTLA-4 and CD28 and their mRNAs in chronic inflammatory demyelinating polyneuropathy","volume":"123","author":"Murata","year":"2000","journal-title":"Brain"},{"key":"10.1016\/j.bbadis.2014.06.013_bb0125","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1136\/jnnp.69.3.362","article-title":"Enhanced B7 costimulatory molecule expression in infl ammatory human sural nerve biopsies","volume":"69","author":"Kiefer","year":"2000","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.bbadis.2014.06.013_bb0130","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1093\/brain\/awf070","article-title":"Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10","volume":"125","author":"Kieseier","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.bbadis.2014.06.013_bb0135","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1212\/01.wnl.0000250240.99311.9d","article-title":"Expression of CD28-related costimulatory molecule and its ligand in inflammatory neuropathies","volume":"68","author":"Hu","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.bbadis.2014.06.013_bb0140","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1084\/jem.194.5.677","article-title":"Development of spontaneous autoimmune peripheral polyneuropathy in B7-2-deficient NOD mice","volume":"194","author":"Salomon","year":"2001","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0145","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1212\/WNL.0b013e318245d250","article-title":"CD8+ T-cell immunity in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"78","author":"Schneider-Hohendorf","year":"2012","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.bbadis.2014.06.013_bb0150","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1212\/WNL.0b013e31827debad","article-title":"Recovery of the T-cell repertoire in CIDP by IV immunoglobulins","volume":"80","author":"Mausberg","year":"2013","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1016\/j.bbadis.2014.06.013_bb0155","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s10875-014-0024-5","article-title":"Mechanistic effects of IVIg in neuroinflammatory diseases: conclusions based on clinicopathologic correlations","volume":"34","author":"Dalakas","year":"2014","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0160","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1529-8027.2010.00294.x","article-title":"Distribution of Th17 cells and Th1 cells in peripheral blood and cerebrospinal fluid in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"15","author":"Chi","year":"2010","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0165","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1529-8027.2008.00158.x","article-title":"Impairment of circulating CD4+CD25+ regulatory T cells in patients with chronic inflammatory demyelinating polyradiculoneuropathy","volume":"13","author":"Chi","year":"2008","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0170","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3109\/08916930903140907","article-title":"Circulating subsets and CD4(+)CD25(+) regulatory T cell function in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"42","author":"Sanvito","year":"2009","journal-title":"Autoimmunity"},{"key":"10.1016\/j.bbadis.2014.06.013_bb0175","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/ana.410300110","article-title":"Serum interleukin-2 concentrations in Guillain\u2013Barre syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: comparison with other neurological diseases of presumed immunopathogenesis","volume":"30","author":"Hartung","year":"1991","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0180","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/jnnp.73.3.320","article-title":"Expression of chemokines in cerebrospinal fluid and serum of patients with chronic inflammatory demyelinating polyneuropathy","volume":"73","author":"Mahad","year":"2002","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.bbadis.2014.06.013_bb0185","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0165-5728(93)90284-6","article-title":"Interleukin-6 levels in the cerebrospinal fluid and serum of patients with Guillain\u2013Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy","volume":"47","author":"Maimone","year":"1993","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0190","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1212\/WNL.44.5.946","article-title":"Expression of endothelial leukocyte adhesion molecule-1 (ELAM-1) in chronic inflammatory demyelinating polyneuropathy","volume":"44","author":"Oka","year":"1994","journal-title":"Neurology"},{"issue":"1\u20132","key":"10.1016\/j.bbadis.2014.06.013_bb0195","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jneuroim.2004.10.021","article-title":"Gene expression profiling in chronic inflammatory demyelinating polyneuropathy","volume":"159","author":"Renaud","year":"2005","journal-title":"J. Neuroimmunol."},{"issue":"1\u20132","key":"10.1016\/j.bbadis.2014.06.013_bb0200","first-page":"115","article-title":"Differential gene expression in chronic inflammatory demyelinating polyneuropathy (CIDP) skin biopsies","volume":"290","author":"Lee","year":"2010","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0205","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/archneur.1980.00500590061010","article-title":"Immunoglobulin and complement deposits in nerves of patients with chronic relapsing polyneuropathy","volume":"37","author":"Dalakas","year":"1980","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0210","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1212\/WNL.30.8.864","article-title":"CSF monoclonal bands in chronic relapsing polyneuropathy","volume":"30","author":"Dalakas","year":"1980","journal-title":"Neurology"},{"key":"10.1016\/j.bbadis.2014.06.013_bb0215","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/0022-510X(92)90217-9","article-title":"Antibodies to acidic glycolipids in Guillain Barre' syndrome and chronic inflammatory demyelinating polyneuropathy","volume":"107","author":"Ilyas","year":"1992","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0220","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/(SICI)1097-4598(200006)23:6<895::AID-MUS8>3.0.CO;2-G","article-title":"Anti-SGPG antibody in CIDP: a nosological position of IgM anti-MAG\/SGPG antibody-associated neuropathy","volume":"23","author":"Tagawa","year":"2000","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.bbadis.2014.06.013_bb0225","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/1531-8249(200006)47:6<765::AID-ANA9>3.0.CO;2-8","article-title":"Passive transfer of demyelination by serum or IgG from chronic inflammatory demyelinating polyneuropathy patients","volume":"47","author":"Yan","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0230","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ana.1129","article-title":"P0 protein is a target antigen in chronic infl ammatory demyelinating polyradiculoneuropathy","volume":"50","author":"Yan","year":"2001","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0235","doi-asserted-by":"crossref","first-page":"4788","DOI":"10.1073\/pnas.0807319106","article-title":"Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic infl ammatory demyelinating polyneuropathy","volume":"106","author":"Tackenberg","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0240","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1212\/WNL.46.3.822","article-title":"Chronic inflammatory demyelinating polyneuropathy associated with malignant melanoma","volume":"46","author":"Bird","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.bbadis.2014.06.013_bb0245","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1212\/WNL.51.6.1738","article-title":"Molecular mimicry in chronic inflammatory demyelinating polyneuropathy and melanoma","volume":"51","author":"Weiss","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.bbadis.2014.06.013_bb0250","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1529-8027.2011.00323.x","article-title":"CIDP-the relevance of recent advances in Schwanncell\/axonal neurobiology","volume":"16","author":"Pollard","year":"2011","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0255","doi-asserted-by":"crossref","first-page":"e14533","DOI":"10.1371\/journal.pone.0014533","article-title":"Nodes of Ranvier and paranodes in chronic acquired neuropathies","volume":"6","author":"Cifuentes-Diaz","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bbadis.2014.06.013_bb0260","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1093\/brain\/awn281","article-title":"Disruption of neurofascin and gliomedin at nodes of Ranvier precedes demyelination in experimental allergic neuritis","volume":"132","author":"Lonigro","year":"2009","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.bbadis.2014.06.013_bb0265","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1042\/AN20130025","article-title":"Node of Ranvier disruption as a cause of neurological diseases","volume":"5","author":"Susuki","year":"2013","journal-title":"ASN Neuro"},{"key":"10.1016\/j.bbadis.2014.06.013_bb0270","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1529-8027.2012.00372.x","article-title":"Nodal proteins are target antigens in Guillain\u2013Barr\u00e9 syndrome","volume":"17","author":"Devaux","year":"2012","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0275","first-page":"288","article-title":"Antineurofascin antibodies are present in patients with peripheral demyelinating neuropathies and mediate changes in nerve conduction in animals","volume":"15","author":"Yan","year":"2010","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0280","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1212\/WNL.0b013e3182a1aa9c","article-title":"Anti-neurofascin antibody in patients with combined central and peripheral demyelination","volume":"81","author":"Kawamura","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.bbadis.2014.06.013_bb0285","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1212\/WNL.0b013e31827689ad","article-title":"Neurofascin as a target for autoantibodies in peripheral neuropathies","volume":"79","author":"Ng","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.bbadis.2014.06.013_bb0290","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/ana.23794","article-title":"Antibody to contactin-1 in chronic inflammatory demyelinating polyneuropathy","volume":"73","author":"Querol","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0295","article-title":"Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg","volume":"2014","author":"Querol","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.bbadis.2014.06.013_bb0300","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1212\/WNL.0b013e3181bd1139","article-title":"Single nucleotide polymorphism of TAG-1 influences IVIg responsiveness of Japanese patients with CIDP","volume":"73","author":"Iijima","year":"2009","journal-title":"Neurology"},{"issue":"Suppl. 15","key":"10.1016\/j.bbadis.2014.06.013_bb0305","first-page":"S73","article-title":"Are anti-TAG-1 autoantibodies markers in autoimmune demyelinating disorders of the PNS and CNS?","volume":"70","author":"Alexopoulos","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0310","doi-asserted-by":"crossref","first-page":"P05.159","DOI":"10.1212\/WNL.78.1_MeetingAbstracts.P05.159","article-title":"Search for nodal and paranodal autoantibodies in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)","volume":"78","author":"Pavlakis","year":"2012","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.bbadis.2014.06.013_bb0315","article-title":"Search for autoantibodies targeting the nodes of Ranvier in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"82","author":"Stathopoulos","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.bbadis.2014.06.013_bb0320","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/ana.410100109","article-title":"Polyneuropathy and monoclonal gammopathy: studies of 11 patients","volume":"10","author":"Dalakas","year":"1981","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0325","doi-asserted-by":"crossref","first-page":"7139","DOI":"10.1073\/pnas.78.11.7139","article-title":"Plasma cell dyscrasia and peripheral neuropathy: identification of the myelin antigens that react with human paraproteins","volume":"78","author":"Latov","year":"1981","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0330","first-page":"301","article-title":"Peripheral neuropathy and anti-MAG antibodies","volume":"3","author":"Latov","year":"1988","journal-title":"Crit. Rev. Neurobiol."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0335","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1073\/pnas.81.4.1225","article-title":"IgM in a human neuropathy related to paraproteinemia binds to a carbohydrate determinant in the myelin-associated glycoprotein and to a ganglioside","volume":"81","author":"Ilyas","year":"1984","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0340","doi-asserted-by":"crossref","first-page":"6697","DOI":"10.1073\/pnas.82.19.6697","article-title":"Polyneuropathy with monoclonal gammopathy: glycolipids are frequently antigens for IgM paraproteins","volume":"82","author":"Ilyas","year":"1985","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0345","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/ana.410310621","article-title":"Sensory neuropathy associated with monoclonal IgM to GD1b ganglioside","volume":"31","author":"Duane","year":"1992","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0350","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1172\/JCI118526","article-title":"Do antiganglioside antibodies cause human peripheral neuropathies?","volume":"97","author":"Quarles","year":"1996","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0355","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1056\/NEJM199003083221002","article-title":"Complement dependent demyelination in patients with IgM monoclonal gammopathy and polyneuropathy","volume":"322","author":"Monaco","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0360","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/ana.20364","article-title":"IgM deposits on skin nerves in anti-myelin-associated glycoprotein neuropathy","volume":"57","author":"Lombardi","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0365","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/mus.880111111","article-title":"Demyelination induced by intraneural injection of human antimyelin associated glycoprotein antibodies","volume":"11","author":"Willison","year":"1988","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.bbadis.2014.06.013_bb0370","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/ana.410330514","article-title":"Experimental paraprotein neuropathy; demyelination by passive transfer of human IgM anti-MAG","volume":"33","author":"Tatum","year":"1993","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0375","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jneuroim.2007.10.025","article-title":"Induction of experimental ataxic sensory neuronopathy in cats by immunization with purified SGPG","volume":"193","author":"Ilyas","year":"2008","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0380","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1212\/WNL.61.6.736","article-title":"Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: immunotherapy for Guillain\u2013Barr\u00e9 syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"61","author":"Hughes","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.bbadis.2014.06.013_bb0385","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","article-title":"Intravenous immune globulin (10% caprylate\u2013chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial","volume":"7","author":"Hughes","year":"2008","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0390","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/ana.410360607","article-title":"A plasma exchange versus immune globulin infusion trial in chronic infl amatory demyelinating polyradiculoneuropathy","volume":"36","author":"Dyck","year":"1994","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0395","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ana.410400516","article-title":"A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy","volume":"40","author":"Dalakas","year":"1996","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0400","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ana.21577","article-title":"Placebo-controlled trial of rituximab in IgM anti-myelin associated glycoprotein antibody demyelinating neuropathy","volume":"65","author":"Dalakas","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0405","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003280.pub3","article-title":"Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for CIDP","author":"Mahdi-Rodgers","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0410","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1212\/WNL.0b013e3181d1a862","article-title":"Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"74","author":"Hughes","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.bbadis.2014.06.013_bb0415","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S1474-4422(08)70299-0","article-title":"Randomised controlled trial of methotrexate for chronic infl ammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study","volume":"8","author":"RMC Trial Group","year":"2009","journal-title":"Lancet Neurol."},{"issue":"Suppl. 1","key":"10.1016\/j.bbadis.2014.06.013_bb0420","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1529-8027.2011.00311.x","article-title":"Potential biomarkers for monitoring therapeutic responses to IVIg and other therapies in CIDP","author":"Dalakas","year":"2011","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0425","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/ana.21737","article-title":"Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain\u2013Barr\u00e9 syndrome","volume":"66","author":"Kuitwaard","year":"2009","journal-title":"Ann. Neurol."},{"issue":"24","key":"10.1016\/j.bbadis.2014.06.013_bb0430","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1212\/WNL.0b013e318296e92b","article-title":"Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy","volume":"80","author":"L\u00e9ger","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.bbadis.2014.06.013_bb0435","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.2012.06832.x","article-title":"Biologics and other novel approaches as new therapeutic options in myasthenia gravis: a view to the future","volume":"1274","author":"Dalakas","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"9","key":"10.1016\/j.bbadis.2014.06.013_bb0440","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.autrev.2013.03.006","article-title":"Novel future therapeutic options in myasthenia gravis","volume":"12","author":"Dalakas","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0445","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/ncpneuro0901","article-title":"B cells as therapeutic targets in autoimmune neurological disorders","volume":"4","author":"Dalakas","year":"2008","journal-title":"Nat. Clin. Pract. Neurol."},{"key":"10.1016\/j.bbadis.2014.06.013_bb0450","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1136\/jnnp.2009.188912","article-title":"Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature","volume":"82","author":"Benedetti","year":"2011","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.bbadis.2014.06.013_bb0455","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/1756285609356135","article-title":"Practical considerations on the use of rituximab in autoimmune neurological disorders","volume":"3","author":"Kosmidis","year":"2010","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"2","key":"10.1016\/j.bbadis.2014.06.013_bb0460","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1529-8027.2011.00328.x","article-title":"An open label clinical trial of complement inhibition in multifocal motor neuropathy","volume":"16","author":"Fitzpatrick","year":"2011","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"1","key":"10.1016\/j.bbadis.2014.06.013_bb0465","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/mus.23839","article-title":"A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis","volume":"48","author":"Howard","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.bbadis.2014.06.013_bb0470","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/archneurol.2010.143","article-title":"Natalizumab treatment in a patient with chronic inflammatory demyelinating polyneuropathy","volume":"67","author":"Wolf","year":"2010","journal-title":"Arch. Neurol."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443914001781?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443914001781?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T05:51:10Z","timestamp":1538545870000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0925443914001781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":94,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S0925443914001781"],"URL":"https:\/\/doi.org\/10.1016\/j.bbadis.2014.06.013","relation":{},"ISSN":["0925-4439"],"issn-type":[{"value":"0925-4439","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathogenesis of immune-mediated neuropathies","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbadis.2014.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}